Abiraterone acetate for the treatment of prostate cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
   PubMed Web of Science ®Google Scholar
• Gregory CW, He B, Johnson RT, A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-19
   PubMed Web of Science ®Google Scholar
• Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25
   PubMed Web of Science ®Google Scholar
• Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207-23
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9
   PubMed Web of Science ®Google Scholar
• Zhang XMC, Sun S, Ketchandji M, Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011;6:e27970
   PubMed Web of Science ®Google Scholar
• Loose DS, Kan PB, Hirst MA, Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983;71:1495-9
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov 2011;10:573-4
   Google Scholar
• Haidar S, Ehmer PB, Barassin S, Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 2003;84:555-62
   Google Scholar
• Jagusch C, Negri M, Hille UE, Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Bioorg Med Chem 2008;16:1992-2010
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8
   PubMed Web of Science ®Google Scholar
• ZYTIGA label. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf
   Google Scholar
• Attard G, Reid AH, A'Hern R, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Shah S, Efstathiou E, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854-61
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012;30(Suppl):abstract LBA4518
   Google Scholar
• Ryan C, Li J, Kheoh T, Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 phase 3 randomized trial. Cancer Res 2012;72(8 Suppl):abstract nr LB-434
   Google Scholar
• Cai C, Chen S, Ng P, Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71:6503-13
   PubMed Web of Science ®Google Scholar
• Ratain MJ. Flushing oral oncology drugs down the toilet. J Clin Oncol 2011;29:3958-9
   PubMed Web of Science ®Google Scholar
• Taplin M, Montgomery R, Logothetis C, Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study. J Clin Oncol 2012;30(Suppl):abstract 4521
   Google Scholar